Vimarsana
Biggest News Aggregation in the World

Page 10 - Kaplan Meier News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Kaplan Meier. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Kaplan Meier Today - Breaking & Trending Today

Prosthesis-Patient Mismatch Tied to Increased Mortality in TAVR - Vimarsana News

Prosthesis-Patient Mismatch Tied to Increased Mortality in TAVR

Although it is known that prosthesis-patient mismatch causes worse outcomes in surgical aortic valve replacement, a new meta-analysis shows this is also the case in transcatheter procedures.

Study Explores Gender Differences in Pediatric Melanoma - Vimarsana News

Study Explores Gender Differences in Pediatric Melanoma

The study is 'the first to explore gender differences in detail in pediatric and adolescent patients with melanoma,' according to one of the investigators.

Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Ipilimumab in Patients with Relapsed, Refractory, Metastatic Sarcomas - Vimarsana News

Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Ipilimumab in Patients with Relapsed, Refractory, Metastatic Sarcomas

Data Show INT230-6 is Well Tolerated and Elicits Both Direct Tumor Killing and Immune Activating Effects in a Variety of Sarcomas In a Heavily Pre-Treated,...

Ferring Pharmaceuticals: Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic - Vimarsana News

Ferring Pharmaceuticals: Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic

New subgroup analyses presented at Digestive Disease Week (DDW) 2022 on the integrated efficacy results of Phase 2b and Phase 3 clinical studies of RBX2660. Data adds to the growing body

Olumiant Approved for COVID-19 Treatment in Hospitalized Adults - Vimarsana News

Olumiant Approved for COVID-19 Treatment in Hospitalized Adults

The FDA has approved Olumiant (baricitinib) for the treatment of COVID-19 in certain hospitalized adults.

Source: empr.com